Pembrolizumab + Defactinib In Pleural Mesothelioma
Status:
Withdrawn
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This research study is studying a new drug combination of Pembrolizumab and Defactinib
followed by surgical resection possible treatment for resectable Malignant Pleural
Mesothelioma (MPM).
The names of the study drugs involved in this study are:
- Pembrolizumab
- Defactinib